Cargando…

Influence of HLA Matching on the Efficacy of Allogeneic Mesenchymal Stromal Cell Therapies for Osteoarthritis and Degenerative Disc Disease

BACKGROUND: The necessity for more effective therapies for chronic osteoarticular diseases has led to the development of treatments based on mesenchymal stem cells (MSCs), the natural precursors of musculoskeletal tissue. Treatments with autologous MSCs yielded excellent results, with nearly 70% imp...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Sancho, Javier, Sánchez, Ana, Vega, Aurelio, Noriega, David C., Nocito, Mercedes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585421/
https://www.ncbi.nlm.nih.gov/pubmed/28894792
http://dx.doi.org/10.1097/TXD.0000000000000724
_version_ 1783261622148530176
author García-Sancho, Javier
Sánchez, Ana
Vega, Aurelio
Noriega, David C.
Nocito, Mercedes
author_facet García-Sancho, Javier
Sánchez, Ana
Vega, Aurelio
Noriega, David C.
Nocito, Mercedes
author_sort García-Sancho, Javier
collection PubMed
description BACKGROUND: The necessity for more effective therapies for chronic osteoarticular diseases has led to the development of treatments based on mesenchymal stem cells (MSCs), the natural precursors of musculoskeletal tissue. Treatments with autologous MSCs yielded excellent results, with nearly 70% improvement of pain and disability in osteoarthritis and degenerative disc disease. Using allogeneic MSCs is logistically more convenient and would widen the pool of eligible patients, but potential immune rejection should be considered. In this context, MSCs are purportedly immune evasive and better tolerated than other cell types. METHODS: We used samples collected during the performance of 2 randomized clinical trials using allogeneic bone marrow MSCs for treatment of osteoarthritis (NCT01586312) and degenerative disc disease (NCT01860417). Serum samples were used to determine anti-HLA antibodies, whereas either blood or MSC samples were used for HLA typing of recipients and donors, respectively. Algofunctional indexes were used as indicators of clinical evolution, and the correlation between the number of donor-host HLA mismatches and the efficacy of treatment was determined. RESULTS: Immune response was weak and transient, with reactivity decaying during the first year. Consistently, better donor-recipient HLA matching did not enhance efficacy. CONCLUSIONS: This lack of reactivity is presumably due to the cooperation of 2 factors, (1) downregulation of the host immune responses by the transplanted MSCs and (2) effective insulation of these cells inside the articular cavity or the intervertebral disc, respectively. Interestingly, better HLA matching did not enhance efficacy. These observations have medical relevance as they support the clinical use of allogeneic cells, at least as a single-dose administration. Multiple-dose applications will require further research to exclude possible sensitization.
format Online
Article
Text
id pubmed-5585421
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-55854212017-09-11 Influence of HLA Matching on the Efficacy of Allogeneic Mesenchymal Stromal Cell Therapies for Osteoarthritis and Degenerative Disc Disease García-Sancho, Javier Sánchez, Ana Vega, Aurelio Noriega, David C. Nocito, Mercedes Transplant Direct Cell Therapy BACKGROUND: The necessity for more effective therapies for chronic osteoarticular diseases has led to the development of treatments based on mesenchymal stem cells (MSCs), the natural precursors of musculoskeletal tissue. Treatments with autologous MSCs yielded excellent results, with nearly 70% improvement of pain and disability in osteoarthritis and degenerative disc disease. Using allogeneic MSCs is logistically more convenient and would widen the pool of eligible patients, but potential immune rejection should be considered. In this context, MSCs are purportedly immune evasive and better tolerated than other cell types. METHODS: We used samples collected during the performance of 2 randomized clinical trials using allogeneic bone marrow MSCs for treatment of osteoarthritis (NCT01586312) and degenerative disc disease (NCT01860417). Serum samples were used to determine anti-HLA antibodies, whereas either blood or MSC samples were used for HLA typing of recipients and donors, respectively. Algofunctional indexes were used as indicators of clinical evolution, and the correlation between the number of donor-host HLA mismatches and the efficacy of treatment was determined. RESULTS: Immune response was weak and transient, with reactivity decaying during the first year. Consistently, better donor-recipient HLA matching did not enhance efficacy. CONCLUSIONS: This lack of reactivity is presumably due to the cooperation of 2 factors, (1) downregulation of the host immune responses by the transplanted MSCs and (2) effective insulation of these cells inside the articular cavity or the intervertebral disc, respectively. Interestingly, better HLA matching did not enhance efficacy. These observations have medical relevance as they support the clinical use of allogeneic cells, at least as a single-dose administration. Multiple-dose applications will require further research to exclude possible sensitization. Lippincott Williams & Wilkins 2017-08-17 /pmc/articles/PMC5585421/ /pubmed/28894792 http://dx.doi.org/10.1097/TXD.0000000000000724 Text en Copyright © 2017 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Cell Therapy
García-Sancho, Javier
Sánchez, Ana
Vega, Aurelio
Noriega, David C.
Nocito, Mercedes
Influence of HLA Matching on the Efficacy of Allogeneic Mesenchymal Stromal Cell Therapies for Osteoarthritis and Degenerative Disc Disease
title Influence of HLA Matching on the Efficacy of Allogeneic Mesenchymal Stromal Cell Therapies for Osteoarthritis and Degenerative Disc Disease
title_full Influence of HLA Matching on the Efficacy of Allogeneic Mesenchymal Stromal Cell Therapies for Osteoarthritis and Degenerative Disc Disease
title_fullStr Influence of HLA Matching on the Efficacy of Allogeneic Mesenchymal Stromal Cell Therapies for Osteoarthritis and Degenerative Disc Disease
title_full_unstemmed Influence of HLA Matching on the Efficacy of Allogeneic Mesenchymal Stromal Cell Therapies for Osteoarthritis and Degenerative Disc Disease
title_short Influence of HLA Matching on the Efficacy of Allogeneic Mesenchymal Stromal Cell Therapies for Osteoarthritis and Degenerative Disc Disease
title_sort influence of hla matching on the efficacy of allogeneic mesenchymal stromal cell therapies for osteoarthritis and degenerative disc disease
topic Cell Therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585421/
https://www.ncbi.nlm.nih.gov/pubmed/28894792
http://dx.doi.org/10.1097/TXD.0000000000000724
work_keys_str_mv AT garciasanchojavier influenceofhlamatchingontheefficacyofallogeneicmesenchymalstromalcelltherapiesforosteoarthritisanddegenerativediscdisease
AT sanchezana influenceofhlamatchingontheefficacyofallogeneicmesenchymalstromalcelltherapiesforosteoarthritisanddegenerativediscdisease
AT vegaaurelio influenceofhlamatchingontheefficacyofallogeneicmesenchymalstromalcelltherapiesforosteoarthritisanddegenerativediscdisease
AT noriegadavidc influenceofhlamatchingontheefficacyofallogeneicmesenchymalstromalcelltherapiesforosteoarthritisanddegenerativediscdisease
AT nocitomercedes influenceofhlamatchingontheefficacyofallogeneicmesenchymalstromalcelltherapiesforosteoarthritisanddegenerativediscdisease